AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02347761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 50 mcg BID eFlow (CS) nebulizer
Description: SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
Study NCT02347761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN-101 25 mcg BID eFlow (CS) nebulizer
Description: SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
Study NCT02347761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID eFlow Closed System (CS) nebulizer
Description: Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
Study NCT02052505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medication review
Description: The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
Study NCT05372835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: La Chlogen mouthwash
Description: Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
Study NCT05372835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
Study NCT00781300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.5%
Description: Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
Study NCT00781300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1%
Description: The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega-3 supplementation (300-400mg EPA \& 200-300mg DHA) per day for 8 consecutive months up to 10 months
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: 50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study NCT05372835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: La Chlogen mouthwash and La Chlogen periodontal flosser
Description: Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
Study NCT01496001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy, axillary block dissection, breast conserving surgery
Description: Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
Study NCT01496001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Adjuvant radiotherapy carried out by institutional protocols.
Study NCT01694160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Zemplar (paricalcitol) 2ug daily, oral intake
Study NCT04141241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecklonia cava Phlorotannin
Description: Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
Study NCT04141241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecklonia cava Phlorotannin
Description: Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
Study NCT00982332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
Study NCT00982332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic sodium chloride solution (placebo)
Description: 4 ml intramuscular
Study NCT01843699 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 4-session gambling cognitive restructuring
Study NCT01843699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-session gambling cognitive restructuring
Study NCT00982332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic sodium chloride solution (placebo)
Description: 4 ml intramuscular
Study NCT01117922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
Study NCT01117922 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Group
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: 50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins (Cardiovascular Agents)
Description: 50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study NCT01346059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
Study NCT01346059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
Study NCT03321500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Versacryl soft liner
Description: Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
Study NCT03321500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silicone-based soft liner
Description: gold standard for denture relining material
Study NCT01611935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressin
Description: After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
Study NCT01611935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
Study NCT04122742 — intervention group
Intervention type: PROCEDURE
Intervention: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.
Description: Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
Study NCT04122742 — intervention group
Intervention type: OTHER
Intervention: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy
Description: induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
Study NCT04122742 — intervention group
Intervention type: OTHER
Intervention: Histone acetylation profiles of cells of SRT patients with CREBBP mutations
Description: Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
Study NCT04122742 — intervention group
Intervention type: OTHER
Intervention: Functional involvement of identified epigenetic alterations
Description: Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
Study NCT04122742 — intervention group
Intervention type: BIOLOGICAL
Intervention: Culture of lymphoblastoid line from blood sample
Description: Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
Study NCT03437863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
Study NCT01538277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact Force during ablation
Description: Radio Frequency Ablation procedure with real-time contact force information known to the operator
Study NCT01538277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ablation procedure
Description: Standard ablation procedure
Study NCT02909712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine (SP)
Description: Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing.
Study NCT02909712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHA-PQP)
Description: Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
Study NCT01733940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of a dressing with clorhexidine gluconate in intravascular catheters.
Study NCT01733940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of a dressing without clorhexidine gluconate
Study NCT02810041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yoghurts enriched with XXS
Study NCT02810041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: yoghurts non enriched with XXS
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxy Urea
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxy Urea
Description: 50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
Study NCT01021683 — intervention group
Intervention type: DRUG
Intervention: Itraconazole
Description: Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
Study NCT01817868 — intervention group
Intervention type: OTHER
Intervention: Recombinant Factor VIII (Kogenate, BAY14-2222)
Description: All dosage, frequency and duration for drugs will be under the decision of the treating physician.
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid Supplementation
Description: Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid Supplementation
Description: Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
Study NCT04301336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine medication as a pain killer is administered, if Patient weight \<50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
Study NCT04301336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Study NCT04301336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood transfusion session
Description: Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.
Study NCT00606372 — intervention group
Intervention type: PROCEDURE
Intervention: OPCAB - the off-pump coronary artery bypass
Description: surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
Study NCT01440153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
Study NCT01440153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Intervention
Description: Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
Study NCT04745182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASTERY
Description: A 12-week, phone-delivered intervention utilizing positive psychology (PP), motivational interviewing (MI), and specific midlife modules (e.g., on time management, financial stress, caregiving stress, or occupational stress) to promote physical activity and well-being in mid-life adults.
Study NCT03588208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training program
Description: Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
Study NCT03588208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: Structured education program were performed during one hour class once a week for five weeks
Study NCT03588208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program
Description: Structured education program were performed during one hour class once a week for five weeks
Study NCT00315250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]β-CIT
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Study NCT01763931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin once daily for 2 weeks prior to definitive breast surgery.
Study NCT04082949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis
Description: The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
Study NCT04082949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis
Description: Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
Study NCT02081846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Home Visit
Description: We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
Study NCT02081846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.